Location History:
- Tucson, AZ (US) (2008)
- Houston, TX (US) (2009 - 2010)
Company Filing History:
3 out of 6 
2 out of 1,863 
2 out of 972 Years Active: 2008-2010
Title: Lynn D Kirkpatrick: Pioneering Innovations in Cancer Treatment
Introduction
Lynn D Kirkpatrick, an innovative inventor based in Houston, TX, has made significant contributions to the field of cancer treatment through his groundbreaking research and patents. With a total of four patents to his name, his work focuses on the development of novel methods and compounds aimed at improving patient outcomes in oncology.
Latest Patents
Kirkpatrick's recent patents reflect his commitment to advancing cancer therapeutics. The first patent covers "Wortmannin analogs and methods of using same in combination with chemotherapeutic agents." This invention describes novel wortmannin analogs that inhibit PI-3-kinase activity in mammals, showcasing their potential in treating or preventing cancer and tumor formation. These analogs can be effectively administered alongside other chemotherapeutic agents, underscoring their role in comprehensive cancer therapies.
The second patent relates to "Methods of identifying respondents to hypoxia inducible factor 1-α inhibitors." This invention details methods for measuring HIF expression and activity, enabling the identification of individuals who are likely to benefit from HIF inhibitors. Moreover, it provides techniques for monitoring patient responses to specific dosages of HIF inhibitors, along with assays and kits designed for these methods, marking a significant advancement in personalized cancer treatment strategies.
Career Highlights
Throughout his career, Lynn D Kirkpatrick has worked with prominent organizations like Prolx Pharmaceuticals Corporation and the University of Arizona. His professional journey has been marked by a dedication to finding effective solutions in the face of challenging medical conditions, particularly in the realm of cancer research.
Collaborations
Kirkpatrick has collaborated with esteemed colleagues such as Garth Powis and Peter Wipf. These partnerships have driven forward the research and development of novel cancer therapies, reflecting the collaborative nature of advancements in medical science.
Conclusion
Lynn D Kirkpatrick stands out as a pioneering inventor in cancer treatment research. His contributions, encapsulated in his latest patents, demonstrate his commitment to enhancing therapeutic approaches for cancer patients. As the landscape of cancer treatment continues to evolve, innovators like Kirkpatrick play a crucial role in shaping future advancements in this vital field.